The authors aimed to evaluate the relationship between concentrations of pioglitazone and its active metabolites and treatment outcomes in patients with nonalcoholic steatohepatitis (NASH) .This study demonstrates the importance of pioglitazone exposure to variable response in patients with NASH, and indicates potential factors that may identify patients most likely to benefit from chronic pioglitazone treatment.
Kawaguchi-Suzuki, M, Bril F, Kalavalapalli S, Cusi K, Frye RF. (2017). Concentration-dependent Response to Pioglitazone in Nonalcoholic Steatohepatitis. Aliment Pharmacol Ther doi: 10.1111/apt.14111.